158 related articles for article (PubMed ID: 1721315)
41. Comparison of FK-506, rapamycin, ascomycin, and cyclosporine in mouse models of host-versus-graft disease and heterotopic heart transplantation.
Mollison KW; Fey TA; Krause RA; Thomas VA; Mehta AP; Luly JR
Ann N Y Acad Sci; 1993 Jun; 685():55-7. PubMed ID: 7689812
[No Abstract] [Full Text] [Related]
42. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction.
Sigal NH; Dumont FJ
Annu Rev Immunol; 1992; 10():519-60. PubMed ID: 1375473
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of T and B lymphocyte proliferation by rapamycin.
Kay JE; Kromwel L; Doe SE; Denyer M
Immunology; 1991 Apr; 72(4):544-9. PubMed ID: 1709916
[TBL] [Abstract][Full Text] [Related]
44. The immunosuppressive macrolides FK-506 and rapamycin.
Thomson AW
Immunol Lett; 1991 Jul; 29(1-2):105-11. PubMed ID: 1717376
[TBL] [Abstract][Full Text] [Related]
45. FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function.
Pelekanou V; Trezise AE; Moore AL; Kay JE
Transplant Proc; 1991 Dec; 23(6):3200-1. PubMed ID: 1721408
[No Abstract] [Full Text] [Related]
46. Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin.
Bierer BE
Proc Assoc Am Physicians; 1995 Apr; 107(1):28-40. PubMed ID: 8630742
[No Abstract] [Full Text] [Related]
47. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts.
Akselband Y; Harding MW; Nelson PA
Transplant Proc; 1991 Dec; 23(6):2833-6. PubMed ID: 1721292
[No Abstract] [Full Text] [Related]
48. New small molecule immunosuppressants for transplantation: review of essential concepts.
Morris RE
J Heart Lung Transplant; 1993; 12(6 Pt 2):S275-86. PubMed ID: 7508752
[TBL] [Abstract][Full Text] [Related]
49. Evidence that rapamycin has differential effects of IL-4 function. Multiple IL-4 signaling pathways and implications for in vivo use.
Taylor-Fishwick DA; Kahan M; Hiestand P; Ritter MA; Foxwell BM
Transplantation; 1993 Aug; 56(2):368-74. PubMed ID: 7689258
[TBL] [Abstract][Full Text] [Related]
50. Rapamycin: in vitro profile of a new immunosuppressive macrolide.
Sehgal SN; Bansbach CC
Ann N Y Acad Sci; 1993 Jun; 685():58-67. PubMed ID: 8363266
[No Abstract] [Full Text] [Related]
51. Quantitative and temporal analysis of the cellular interaction of FK-506 and rapamycin in T-lymphocytes.
Dumont FJ; Kastner C; Iacovone F; Fischer PA
J Pharmacol Exp Ther; 1994 Jan; 268(1):32-41. PubMed ID: 7507994
[TBL] [Abstract][Full Text] [Related]
52. The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma.
Haczku A; Alexander A; Brown P; Assoufi B; Li B; Kay AB; Corrigan C
J Allergy Clin Immunol; 1994 Feb; 93(2):510-9. PubMed ID: 8120277
[TBL] [Abstract][Full Text] [Related]
53. Comparative effects of rapamycin, FK 506 and cyclosporine on antibody production, lymphocyte populations and immunoglobulin isotype switching in the rat.
Thomson AW; Propper DJ; Woo J; Whiting PH; Milton JI; Macleod AM
Immunopharmacol Immunotoxicol; 1993 Aug; 15(4):355-69. PubMed ID: 7693791
[TBL] [Abstract][Full Text] [Related]
54. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A.
Fruman DA; Klee CB; Bierer BE; Burakoff SJ
Proc Natl Acad Sci U S A; 1992 May; 89(9):3686-90. PubMed ID: 1373887
[TBL] [Abstract][Full Text] [Related]
55. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation.
Hess DA; Bird IA; Almawi WY; Rieder MJ
J Pharmacol Exp Ther; 1997 Apr; 281(1):540-8. PubMed ID: 9103542
[TBL] [Abstract][Full Text] [Related]
56. Suppression of allograft responses by combining alloantigen-specific i.v. presensitization with suboptimal doses of FK 506 or rapamycin.
Iwata H; Nagano T; Toyo-oka K; Hirose H; Hamaoka T; Fujiwara H
Transplant Proc; 1994 Apr; 26(2):851-4. PubMed ID: 7513476
[No Abstract] [Full Text] [Related]
57. Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A.
Metcalfe S; Milner J
Transplantation; 1991 Jun; 51(6):1318-20. PubMed ID: 1710844
[No Abstract] [Full Text] [Related]
58. Cyclosporine A, FK-506, 40-0-[2-hydroxyethyl]rapamycin and mycophenolate mofetil inhibit proliferation of human intrahepatic biliary epithelial cells in vitro.
Liu C; Schreiter T; Frilling A; Dahmen U; Broelsch CE; Gerken G; Treichel U
World J Gastroenterol; 2005 Dec; 11(48):7602-5. PubMed ID: 16437685
[TBL] [Abstract][Full Text] [Related]
59. Interleukin-2 receptor (CD25) upregulation on human T-lymphocytes: sensitivity to immunosuppressants is defined by the mode of T-lymphocyte activation.
Ryffel B; Willcocks JL; Brooks N; Woerly G
Immunopharmacology; 1995 Sep; 30(3):199-207. PubMed ID: 8557519
[TBL] [Abstract][Full Text] [Related]
60. Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures.
Thomson AW; Woo J; Yao GZ; Todo S; Starzl TE; Zeevi A
Transpl Immunol; 1993; 1(2):146-50. PubMed ID: 7521738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
